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Isolated systolic hypertension (ISH) is the common-
the Elderly (EWPHE) who planned the SYS-EUR Study were bold in their outlook, starting recruitest form of hypertension in the elderly population, accounting for roughly 60% of all cases.
1 Prevalence ment while SHEP was in progress and continuing the study with only minor modifications even after rates vary according to age, and of those aged 50 years about 2% will have a systolic blood pressure the results were published. They also took the (SBP) у160 mm Hg and a diastolic BP (DBP) Ͻ90
unprecedented step at that time of using a prevmm Hg compared to 10-15% of those aged 70 years, iously untried first line treatment regimen in the and over 30% in the 80+ age group. 2 Prospective form of one of the newer, longer acting dihydropyristudies have demonstrated that SBP levels are more dine calcium channel blockers (CCBs), nitrendipine, closely related to the incidence of cardiovascular as opposed to the tried and tested diuretics or beta-(CV) events than DBP values in this older popublockers. This was perhaps a fortuitous choice of lation 3 and given the high prevalence rates of ISH, first line agent given the recent concerns regarding it is perhaps surprising that up to now there has the long term safety profile of CCB's, particularly only been one intervention trial specifically aimed with regard to cancer incidence and bleeding comat assessing the effects of antihypertensive therapy plications. The study enrolled 4695 patients Ͼ60 on outcome measures in patients with ISH. The years (mean age 70.3 years and comprising nearly SHEP trial 4 reporting in 1991 showed that BP 50% of those screened) with a sustained SBP of 160-reduction in patients with ISH (defined as SBP у160 219 mm Hg and a DBP Ͻ95 mm Hg taken after a 3 mm Hg and DBP р90 mm Hg) significantly reduced month placebo run-in phase (mean baseline sitting stroke, myocardial infarction and coronary events, BP being 174/86 mm Hg). Eligible patients were but did not reduce stroke or CV mortality unlike stratified by age, sex and previous cardiovascular some other intervention trials in the elderly. [5] [6] [7] complications at each centre and randomised to SHEP used a thiazide diuretic as first line therapy active treatment with nitrendipine (10-40 mg/day) with the addition of a beta-blocker, a regimen in or matching placebo in a double-blind fashion. keeping with the majority of large intervention trials Additional therapy comprised of enalapril (5-in the elderly. There were, however, criticisms of 20 mg/day) and/or hydrochlorothiazide (12.5-this trial in that it was not necessarily representative 25 mg/day) with the aim of reducing sitting SBP by of the general elderly population with ISH (SHEP 20 mm Hg or more to Ͻ150 mm Hg. only recruited 1% of those screened). It also
The patients recruited into the placebo and active appeared that most of those entered were otherwise limbs of SYST-EUR were well matched for age, sex, 'healthy', with a lower than expected CV complicholesterol, body mass index (BMI) and previous CV cation rate at entry and a lower than projected death complications (30%). Median follow-up was just 2 rate in the placebo arm. Confirmation of the SHEP years, the difference between active and placebo results was obviously needed and this has come groups in sitting BP at this time being 10/5 mm Hg recently with the publication of the European Trial with 43.5% and 21.4%, respectively, reaching their on Isolated Systolic Hypertension in the Elderly target BP (P Ͻ 0.001) and nearly 60% of the active (SYST-EUR) 8 , the preliminary reports of which were treatment group remaining on nitrendipine therapy published in the Journal of Human Hypertension. 9, 10 alone. The primary end-point of the study was fatal The European Working Party on Hypertension in or non-fatal stroke and on this basis the trial was terminated at the second interim analysis. Active treatment reduced total stroke incidence by 42%
fatal CV end-points were reduced by 31% to wait a little longer to see if there are potential advantages to be gained in using the newer antihy-(P = 0.001), all cause, CV and stroke mortality were pertensive agents as first line therapy over the more not significantly reduced in the active treatment traditional thiazide/beta-blocker regimens, but at limb of the trial. Of interest, cancer mortality was least the evidence to date suggests a potentially reduced by 31% (95% CI −63 to 26) and bleeding promising future for the dihydropyridine CCB's. episodes by 10% (−52 to 69) in the intervention group. Overall these results for stroke and CV risk reduction are in keeping with the findings of earlier studies. [4] [5] [6] [7] 11 Further, a recent meta-analysis based
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on older patients with combined systolic and diastolic hypertension and ISH, showed a 34% tively short period of time. Secondly, it would 757-764. appear that the newer antihypertensive agents, parti- 
